PerkinElmer grabs license to TIBCO Spotfire

PerkinElmer ($PKI) is raising its "Big Data" game and adding to its growing software offerings for biotech and pharma labs. The Waltham, MA-based company struck a deal with TIBCO Software to be the exclusive worldwide provider of TIBCO's analytics software Spotfire in certain scientific R&D markets.

PerkinElmer and TIBCO didn't reveal any of the specific financials in the agreement. Yet the deal shows that PerkinElmer wants to improve its ability to offer R&D groups technology to analyze and visualize their complex data. And the agreement builds on PerkinElmer's previous moves in the software arena such as the buyouts of CambridgeSoft, ArtusLabs, Labtronics and Geospiza.

Spotfire serves multiple markets such as energy, financial services and defense, yet in life sciences the visual analysis tool supports the discovery of biomarkers and drug targets from huge amounts of biological data, among other uses. PerkinElmer plans to offer Spotfire for preclinical and basic research groups as well as to R&D customers in other industries outside of biopharma.    

"The whole area of data visualization and analysis is the biggest unmet need," Mike Stapleton, general manager of Informatics at PerkinElmer, told The Boston Globe. And Stapleton's group will be able to work closely with Spotfire experts at Palo Alto, CA-based TIBCO's office in Somerville, MA. (TIBCO acquired Somerville-based Spotfire in 2007.)  

- here's the release
- see the Globe's article

Special Report: 10 Reasons Why Biotech Needs Big Data

Related Articles:
PerkinElmer CEO arranges marriage between informatics, lab service biz
PerkinElmer, others ride 'wave' of genomic data going to the cloud
PerkinElmer partners with MGH on informatics system for cancer research

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

The $58 million financing round represents biopharma industry's growing interest in genomics data.

Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system.